◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HighTide Therapeutics, Inc. (2511) Financial History

Name: HighTide Therapeutics, Inc. (2511) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

HighTide Therapeutics, Inc. (2511) operates in the Biotechnology industry and is headquartered in Shenzhen, China with about 51 employees. Its market capitalization is roughly CNY 2 billion. In the fiscal year ended 2025-12-31, 2511 reported CNY 0M in revenue and (CNY 232M) in net income.

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China.

Interactive charts & full statements →

2511 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CNY 0M	CNY 0M	CNY 0M	CNY 0M	—
Operating Income (EBIT)	(CNY 215M)	(CNY 406M)	(CNY 438M)	(CNY 218M)	—
Net Income	(CNY 232M)	(CNY 382M)	(CNY 939M)	(CNY 190M)	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2511 Free Cash Flow History

2511 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 551M	CNY 560M	CNY 795M	CNY 856M	—
Total Liabilities	CNY 187M	CNY 136M	CNY 92M	CNY 1.3B	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2511 viewer.

Other Companies in Biotechnology

KARD · Kardigan, Inc. — $2 billion
SNDX · Syndax Pharmaceuticals, Inc. — $2 billion
RXRX · Recursion Pharmaceuticals, Inc. — $2 billion
FTRE · Fortrea Holdings Inc. — $2 billion
ZYME · Zymeworks Inc. — $2 billion
ANAB · AnaptysBio, Inc. — $2 billion
NANO · Nanobiotix S.A. — $2 billion
TRAX · First Tracks Biotherapeutics, Inc. — $2 billion

← 2510 All “0-9” companies 2512 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.